What is moving
The switching report
What people are dropping, what they are picking up instead, and whether the trial record supports the move.
- Mitophagy and autophagy compounds
- NAD+ precursors
- Senolytics
- GLP-1 adjacent products
This week's switching report
Why long-time NAD+ users are drifting toward urolithin A
Both are sold as cellular energy supplements. Their human evidence bases are built very differently, and buyers are starting to notice.
Tracking
What people drop
Grading
Human trial data
Checking
Labels and doses
Ignoring
Press releases
What we cover
Three questions run through everything here: what are people switching to, what does it do inside the body, and does the label match the bottle.
Glucose and fuel
Metabolic signals
Continuous glucose data, protein, and the metabolic claims attached to almost every product launched this year.
- Continuous glucose monitors
- Post-meal glucose response
- Protein and satiety
- AMPK and metabolic botanicals
What is in the bottle
Label and dose
Bioavailability, standardisation, third-party marks, and the gap between a trialled dose and a marketed one.
- Oral bioavailability
- Certificates of analysis
- Third-party certification
- Serving size arithmetic
Recently reviewed
Each piece gets re-read when new trial data lands. Filter by section to see what changed.
The switching reportWhy long-time NAD+ users are drifting toward urolithin A
Both are sold as cellular energy supplements. Their human evidence bases are built very differently, and buyers are starting to notice.
Metabolic signalsWhat two weeks with a CGM actually teaches a person without diabetes
Over-the-counter glucose sensors are now a pharmacy purchase. Used as a short experiment they are genuinely informative. Worn permanently they mostly generate anxiety.
Label and doseBioavailability is the whole argument, and almost nobody prints it
A compound with excellent trial data can be sold in a product that delivers almost none of it. Absorption is where most supplement disappointment originates.
The switching reportFisetin's dose problem is quietly reshaping how it is sold
The senolytic story is built on mouse data and a handful of human trials. The bigger obstacle for buyers is that most capsules cannot deliver a meaningful dose.
The switching reportThe GLP-1 era rewrote the supplement shelf
Prescription weight-loss drugs changed what people want from a supplement. The industry responded with a wave of products making adjacent claims.
The switching reportSpermidine is outselling its evidence, and one trial may change that
A dietary polyamine with a strong mechanistic case, good observational data, and almost no confirmatory human trial results. A cardiology trial should report soon.
What we are working on
Stories in progress, with roughly where they stand. Vote to tell the desk what to prioritise.
Publishing soon
Creatine's second act: from gym tub to cognition claim
In review
What happened to resveratrol
Drafting
Shilajit: the supply chain nobody wants to discuss
Researching
Do longevity stacks interact with each other
Researching
Price per effective dose across 40 products
Write for us
We take pitches from pharmacologists, dietitians, formulators, and analytical chemists. We do not take pitches from brands.
Ingredient reviews
Walk through the human trial record for one compound, including the trials that found nothing. Dose, format, and duration matter more than mechanism.
Formulation and analysis
How a product is actually made: excipients, standardisation, stability, and what a certificate of analysis does and does not prove.
Market and regulation
Category shifts, recalls, warning letters, and the gap between what a label may legally say and what marketing implies.
What we will and will not publish
- Claims must trace to a named trial, review, registry entry, or regulator document.
- Pieces run 1,200 to 2,500 words and say plainly where the evidence is thin.
- No paid placements, no affiliate copy dressed as reporting, no brand-supplied claims.
- Any commercial relationship, including free product, is disclosed in the byline.
Editors' picks
Longer pieces we keep sending people back to.
The switching reportWhy long-time NAD+ users are drifting toward urolithin A
Both are sold as cellular energy supplements. Their human evidence bases are built very differently, and buyers are starting to notice.
The switching reportThe GLP-1 era rewrote the supplement shelf
Prescription weight-loss drugs changed what people want from a supplement. The industry responded with a wave of products making adjacent claims.
Metabolic signalsWhat two weeks with a CGM actually teaches a person without diabetes
Over-the-counter glucose sensors are now a pharmacy purchase. Used as a short experiment they are genuinely informative. Worn permanently they mostly generate anxiety.